FDA issues complete response letter to Disc Medicine’s bitopertin NDA
Disc Medicine has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) concerning its new…
16 Feb 2026
Immunic secures $400m fund to support commercial-stage development
Immunic has announced an oversubscribed private placement of up to $400m, strengthening its move from an R&D-focused organisation into a commercial-stage entity. The placement was led by existing investor BVF…
13 Feb 2026
European VC firms band together to tackle continent’s lacklustre capital
European venture capital (VC) firms have joined forces to establish the European Life Sciences Coalition (ELSC), the latest move by the continent’s life sciences industry to tackle a slump in…
13 Feb 2026
Preclinical model drawbacks dampen UK innovation, ABPI report says
A report from the Association of the British Pharmaceutical Industry (ABPI) has suggested that a disharmony between academia and industry at the preclinical stage is a key factor stifling UK…
13 Feb 2026
Ampersand Capital acquires Purna Pharmaceuticals
Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector. The move is part of…
13 Feb 2026
Amgen receives EC approval for Uplizna in generalised myasthenia gravis
Amgen has secured approval from the European Commission (EC) for Uplizna (inebilizumab) as an add-on treatment to standard therapy for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor…
12 Feb 2026
Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head
Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi, after the French vaccine specialist announced it would not renew existing CEO Paul Hudson’s contract. The abrupt…